Drug reference
durvalumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Monoclonal antibody(Oncology))
Mechanism of action
Human IgG1 kappa monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80, and therefore overcoming/preventing PD-L1-mediated inhibition/suppression of T-cell activation. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody dependent cell-mediated cytotoxicity.
Common side effects
- Fatigue
- Increased AST
- Lymphopenia
- Hyperglycemia
- Hypocalcemia
- Increased ALT
- Productive cough
Related conditions
Frequently asked questions
What drug class is durvalumab?
durvalumab belongs to: Oncology.
How does durvalumab work?
Human IgG1 kappa monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80, and therefore overcoming/preventing PD-L1-mediated inhibition/suppression of T-cell activation. Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, without inducing antibody dependent cell-mediated cytotoxicity.
What are the common side effects of durvalumab?
Fatigue, Increased AST, Lymphopenia, Hyperglycemia, Hypocalcemia, Increased ALT, Productive cough
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.